Sera Prognostics reports Q4 EPS (25c) vs. (31c) last year

Reports Q4 revenue $41,000 vs. $65,000 last year. “We are looking forward to an exciting year of developments for Sera, including publication of our PRIME study results while executing on commercial expansion and our plans to establish direct relationships with expectant mothers,” said Zhenya Lindgardt, President and CEO of Sera Prognostics. “We expect these activities and advancements in our product pipeline to complement what we believe is our leading position in the area of maternal and neonatal health and pave the way for a future inflection in revenue growth.”